SLC5A2 and chronic kidney disease: Similarly, use of an SGLT-2 inhibitor was associated with a lower incidence of the composite renal outcome in patients without CKD: RR 0.65 (95% CI 0.53–0.80; P < 0.001) (Fig. 4 and Table 3).